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A Clinically Useful Diagnostic Label?*Steffen E. Petersen, MD, DPHIL, MPHSEE PAGE 934L eft ventricular noncompaction (LVNC) is char-acterized by a 2-layered appearance of themyocardium, with a thick inner trabeculated
layer and a thin outer compacted myocardial layer.
Many uncertainties remain with regard to its pre-
valence, pathogenesis, natural history, and the
mechanisms leading to heart failure, malignant ar-
rhythmias, and thromboembolic events. Dilated car-
diomyopathy can lead to the same clinical picture
described in LVNC patients. The little that is known
about the prognosis of LVNC patients with nonische-
mic left ventricular (LV) dilation and systolic
dysfunction is on the basis of small case series and
is thus likely to be confounded by publication bias.
Treatment approaches in LVNC patients are similar
to those in dilated cardiomyopathy; however,
because of a lack of evidence, there is no consensus
as to whether the threshold to treat should be lower
than for dilated cardiomyopathy with regard to
anticoagulation or device implantation (implantable
cardioverter-deﬁbrillator, cardiac resynchronization
therapy).
Stacey et al. (1) recently showed in a retrospective
study that for a number of diagnostic cardiac mag-
netic resonance (CMR) criteria that were similar to but
slightly modiﬁed compared with those in previously
published studies, associations existed with preva-
lent (existing) heart failure and with incident (future)
combined clinical events (death, heart failure read-
mission, embolic events, or ventricular arrhythmias).*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
the authors and do not necessarily represent the views of JACC:
Cardiovascular Imaging or the American College of Cardiology.
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Cardiovascular Imaging.In this issue of iJACC, Amzulescu et al. (2) further
address an important question about the contribution
of the extent of LV trabeculation to prognosis in
dilated cardiomyopathy. In this prospective registry
of 162 patients with dilated cardiomyopathy who
presented with a spectrum of LV trabeculation extent
(from little to excessive), a signiﬁcant proportion
fulﬁlled an imaging diagnosis of LVNC: 37% for CMR
criteria from Petersen et al. (3) and 45% for CMR
criteria from Jacquier et al (4). In these 162 patients
with a median follow-up of 3.4 years, neither the
Petersen (3) nor the Jacquier (4) criteria were inde-
pendent predictors for major adverse cardiovascular
events (MACE). Only LV ejection fraction and late
gadolinium enhancement were independent pre-
dictors of MACE-free survival in multivariate
analyses.This study has potential clinical impact. This new
information already provides some reassurance to
clinicians and patients that management of LVNC
does not require different strategies or treatment
thresholds above the established ones for dilated
cardiomyopathy; however, the study does not provide
enough evidence for a deﬁnitive answer. One of the
major limitations, which is appropriately acknowl-
edged, is related to the small sample size and low
event rates. We can only be 80% conﬁdent that event
rates are not at least 50% different between patients
with and without an imaging criterion for LVNC.
Future larger studies are required to conﬁrm that
smaller differences in event rates are not missed
(false negative result). Effect sizes related to LV
trabeculations are likely to be much smaller than
50%, as used for the sample size calculation in the
report by Amzulescu et al. (2), given that patients
with dilated cardiomyopathy are (presumably) un-
dergoing optimal medical therapy.
Further controversies and uncertainties remain
with regard to the best diagnostic approach. Which
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948image modality and which diagnostic criterion should
be used, and should the measurements be performed
during end diastole or end systole? Fractal dimen-
sion analysis, introduced by Captur et al. (5), is a
promising method of obtaining a more objective
assessment of endocardial complexity; however,
even this approach is not without its limitations,
because it does not take into account the thickness of
the compacted myocardium, which may be a very
important phenotypic marker of real (but rare) dis-
ease. In a recent editorial in iJACC (6), I emphasized
the need to interpret any measure of the degree of LV
trabeculations in the clinical context (to establish the
pre-test probability) when considering an imaging
diagnosis of LVNC.
There is a cost to labeling patients with a new
diagnosis of LVNC when there is not enough evidence
to suggest that the natural history compared with a
reference population is different. This can unneces-
sarily create patient anxiety and can have signiﬁcant
implications for health care resources. To this end,
Zemrak et al. (7) recently demonstrated that the
extent of trabeculations does not predict clinically
relevant adverse cardiac remodeling in an asymp-
tomatic population cohort study. This information
should guide clinical decision making in the commonscenario of identifying patients with marked LV tra-
beculation and low pre-test probability of LVNC, in
that there is no clear need for follow-up imaging or
pharmacotherapy in these patients. The study by
Amzulescu et al. (2) extends this work by showing
that in patients with dilated cardiomyopathy, marked
LV trabeculations do not appear to modify the MACE-
free survival.
Given the remaining uncertainties concerning
LVNC, it is no surprise that the American Heart Asso-
ciation and European Society of Cardiology have
differing opinions as to whether LVNC should be a
distinct cardiomyopathy. Do trabeculations perhaps
just represent an epiphenomenon? Further research is
warranted to answer this question, but until more data
become available, it seems that there is no convincing
evidence to suggest that the degree of trabeculations
has incremental prognostic value in asymptomatic
low-risk populations and in dilated cardiomyopathy.
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